{"disease":{"id":"family-history","name":"family history"},"drugs":{"marketed":[{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":83,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04599218","title":"MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1586,"lead_sponsor_name":"Ardeshir Rastinehad","has_results":false},{"nct_id":"NCT02913664","title":"Risk Reduction for Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":513,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06746623","title":"Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Louis Stokes VA Medical Center","has_results":false},{"nct_id":"NCT05331144","title":"Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Rong Zhang","has_results":false},{"nct_id":"NCT04925076","title":"Characterizing the Effects of Family History of Alcoholism on Alcohol Analgesia","phase":"NA","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT06675994","title":"In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"LifeBridge Health","has_results":false},{"nct_id":"NCT00359710","title":"Patients' Perspectives on Identity, Ancestry and Genetics","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT05872503","title":"Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy","phase":"","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}